NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF

NOVO NORDISK A S

Financials through fiscal 2025, year ended Dec 31, 2025

$38.42−0.41 (-1.06%)

Close on Oct 19, 2026

NOVO NORDISK A S income statement

AnnualQuarterlyTTM

DKK USD

Millions of DKK, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	309,064	290,403	232,261	176,954	140,800	126,946	122,021	111,831	111,696	111,780	107,927
Cost of Revenue	58,788	44,522	35,765	28,448	23,658	20,932	20,088	17,617	17,632	17,183	16,188
Gross Profit	250,276	245,881	196,496	148,506	117,142	106,014	101,933	94,214	94,064	94,597	91,739
Research & Development	52,039	48,062	32,443	24,047	17,772	15,462	14,220	14,805	14,014	14,563	13,608
General & Administrative	5,969	5,276	4,855	4,467	4,050	3,958	4,007	3,916	3,784	3,962	3,857
Operating Income	127,658	128,339	102,574	74,809	58,644	54,126	52,483	47,248	48,967	48,432	49,444
Interest Expense	6,778	7,346	845	5,986	2,451	2,624	3,995	1,755	1,533	726	6,046
Interest & Investment Income	9,660	6,198	2,945	239	2,887	1,628	65	2,122	1,246	92	85
Income from Equity Investments	0	0	81	0	0	149	0	12	14	24	14
Pretax Income	130,540	127,191	104,674	69,062	59,080	53,130	48,553	47,615	48,680	47,798	43,483
Income Tax Expense	28,106	26,203	20,991	13,537	11,323	10,992	9,602	8,987	10,550	9,873	8,623
Net Income incl. Noncontrolling Interests	102,434	100,988	83,683	55,525	47,757	42,138	38,951	38,628	38,130	37,925	34,860
EPS (Basic)(per share)	23.06	22.67	18.67	12.26	10.40	9.03	8.21	7.98	7.71	7.50	6.78
EPS (Diluted)(per share)	23.03	22.63	18.62	12.22	10.37	9.01	8.19	7.97	7.70	7.48	6.76
Shares Outstanding (Basic, Weighted)(shares)	4,443	4,454	4,483	4,531	4,593	4,668	4,749	4,839	4,946	5,060	5,142
Shares Outstanding (Diluted, Weighted)(shares)	4,448	4,463	4,495	4,545	4,606	4,680	4,757	4,849	4,956	5,069	5,155
EBITDA	142,324	136,884	109,863	81,362	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 81.0%
Operating margin: 41.3%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.80
Debt to equity: –
Debt to assets: 26.3%
Cash to current liabilities: 12.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.